Inactive Instrument
DUCAT VENTURES Share Price London S.E.
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 08/09 | OptiBiotix Health plc Provides Update on SweetBiotix Product Range | CI |
| 02/09 | Corero wins deal; Talisman kicks off Tirzzit drilling | AN |
| Market Cap | 61.46L 83.25L 71.64L 67.46L 1.15Cr 79Cr 1.15Cr 7.99Cr 3.09Cr 40Cr 3.13Cr 3.06Cr 127.86Cr | P/E 2024 |
-9.76x | P/E 2025 | -1.76x |
|---|---|---|---|---|---|
| Enterprise Value | 51.09L 69.21L 59.55L 56.08L 95.6L 66Cr 95.98L 6.65Cr 2.57Cr 34Cr 2.6Cr 2.54Cr 106.29Cr | EV / Sales 2024 |
19.4x | EV / Sales 2025 | 5.09x |
| Free-Float |
88.62% | Yield 2024 * |
-
| Yield 2025 | - |
| 16/25/16 | OptiBiotix Health : Financial document (interims 2025) | PU |
| 30/25/30 | OptiBiotix Health : Annual Report (ar2024) | PU |
| 30/25/30 | OptiBiotix Health : Financial document (prelims 2024) | PU |
| 27/24/27 | OptiBiotix Health : Results Report | PU |
| 28/24/28 | OptiBiotix Health : Results Report | PU |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen O'Hara
CEO | Chief Executive Officer | 66 | 05/08/2014 |
David Blain
DFI | Director of Finance/CFO | 65 | 01/11/2024 |
Sofia Kolyda
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Sofia Kolyda
BRD | Director/Board Member | 53 | 04/07/2018 |
Stephen O'Hara
BRD | Director/Board Member | 66 | 05/08/2014 |
Richard Davidson
CHM | Chairman | 75 | 01/01/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.94% | -0.71% | +45.60% | +103.25% | 6.92TCr | ||
| -0.07% | -3.93% | +32.54% | +78.50% | 6.3TCr | ||
| +3.13% | +1.71% | -12.50% | +390.48% | 2.73TCr | ||
| -2.99% | -6.71% | +25.80% | +10.77% | 2.58TCr | ||
| -0.54% | -5.47% | -3.88% | -18.31% | 2.48TCr | ||
| -1.43% | -1.89% | +21.32% | -19.01% | 2.01TCr | ||
| -4.27% | +3.07% | +211.22% | +362.48% | 1.85TCr | ||
| -1.54% | -4.59% | -5.29% | +506.91% | 1.49TCr | ||
| +1.14% | -0.34% | +52.38% | +163.82% | 1.43TCr | ||
| Average | -0.84% | -0.80% | +40.80% | +175.43% | 3.09TCr | |
| Weighted average by Cap. | -0.69% | -1.32% | +37.56% | +139.53% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 9L 11.78L 10.14L 10L 16.28L 11Cr 16.34L 1.13Cr 43.74L 5.71Cr 44.25L 43.29L 18Cr | 11.66L 15.79L 13.59L 12.8L 21.82L 15Cr 21.9L 1.52Cr 58.62L 7.66Cr 59.31L 58.02L 24Cr |
| Net income | -18.05L -24.45L -21.04L -19.81L -33.77L -23Cr -33.91L -2.35Cr -90.74L -12Cr -91.81L -89.81L -38Cr | -38.9L -52.69L -45.34L -42.69L -72.78L -50Cr -73.07L -5.06Cr -1.96Cr -26Cr -1.98Cr -1.94Cr -81Cr |
| Net Debt | -7L -10.01L -9L -8L -13.83L -9.53Cr -13.88L -96.12L -37.15L -4.85Cr -37.59L -36.77L -15Cr | -10.37L -14.05L -12.09L -11.38L -19.4L -13Cr -19.48L -1.35Cr -52.13L -6.81Cr -52.74L -51.6L -22Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















